Literature DB >> 18260132

Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia.

Virginia E Kimonis1, Sarju G Mehta, Erin C Fulchiero, Dana Thomasova, Marzia Pasquali, Kym Boycott, Edward G Neilan, Alex Kartashov, Mark S Forman, Stuart Tucker, Katerina Kimonis, Steven Mumm, Michael P Whyte, Charles D Smith, Giles D J Watts.   

Abstract

Inclusion body myopathy with Paget disease of the bone (PDB) and/or frontotemporal dementia (IBMPFD, OMIM 167320), is a progressive autosomal dominant disorder caused by mutations in the Valousin-containing protein (VCP, p97 or CDC48) gene. IBMPFD can be difficult to diagnose. We assembled data on a large set of families to illustrate the number and type of misdiagnoses that occurred. Clinical analysis of 49 affected individuals in nine families indicated that 42 (87%) of individuals had muscle disease. The majority were erroneously diagnosed with limb girdle muscular dystrophy (LGMD), facioscapular muscular dystrophy, peroneal muscular dystrophy, late adult onset distal myopathy, spinal muscular atrophy, scapuloperoneal muscular dystrophy, or amyotrophic lateral sclerosis (ALS) among others. Muscle biopsies showed rimmed vacuoles characteristic of an inclusion body myopathy in 7 of 18 patients (39%), however, inclusion body myopathy was correctly diagnosed among individuals in only families 5 and 15. Frontotemporal dementia (FTD) was diagnosed in 13 individuals (27%) at a mean age of 57 years (range 48.9-60.2 years); however, several individuals had been diagnosed with Alzheimer disease. Histopathological examination of brains of three affected individuals revealed a pattern of ubiquitin positive neuronal intranuclear inclusions and dystrophic neurites. These families expand the clinical phenotype in IBMPFD, a complex disorder caused by mutations in VCP. The presence of PDB in 28 (57%) individuals suggests that measuring serum alkaline phosphatase (ALP) activity may be a useful screen for IBMPFD in patients with myopathy. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18260132      PMCID: PMC2467391          DOI: 10.1002/ajmg.a.31862

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  30 in total

1.  p97, a protein coping with multiple identities.

Authors:  Philip G Woodman
Journal:  J Cell Sci       Date:  2003-11-01       Impact factor: 5.285

Review 2.  Sequence analysis of the AAA protein family.

Authors:  A Beyer
Journal:  Protein Sci       Date:  1997-10       Impact factor: 6.725

3.  A study of the Lund-Manchester research criteria for frontotemporal dementia: clinical and single-photon emission CT correlations.

Authors:  B L Miller; C Ikonte; M Ponton; M Levy; K Boone; A Darby; N Berman; I Mena; J L Cummings
Journal:  Neurology       Date:  1997-04       Impact factor: 9.910

4.  Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies.

Authors:  M Mirabella; R B Alvarez; M Bilak; W K Engel; V Askanas
Journal:  J Neuropathol Exp Neurol       Date:  1996-07       Impact factor: 3.685

Review 5.  Diagnostic procedures for Paget's disease. Radiologic, pathologic, and laboratory testing.

Authors:  R M Klein; A Norman
Journal:  Endocrinol Metab Clin North Am       Date:  1995-06       Impact factor: 4.741

6.  A new familial disorder of combined lower motor neuron degeneration and skeletal disorganization.

Authors:  W S Tucker; W H Hubbard; T D Stryker; S W Morgan; O B Evans; F R Freemon; G B Theil
Journal:  Trans Assoc Am Physicians       Date:  1982

7.  Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha.

Authors:  R M Dai; E Chen; D L Longo; C M Gorbea; C C Li
Journal:  J Biol Chem       Date:  1998-02-06       Impact factor: 5.157

8.  beta-Amyloid precursor epitopes in muscle fibers of inclusion body myositis.

Authors:  V Askanas; R B Alvarez; W K Engel
Journal:  Ann Neurol       Date:  1993-10       Impact factor: 10.422

9.  Mutation in the tau gene in familial multiple system tauopathy with presenile dementia.

Authors:  M G Spillantini; J R Murrell; M Goedert; M R Farlow; A Klug; B Ghetti
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

10.  Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein.

Authors:  Giles D J Watts; Jill Wymer; Margaret J Kovach; Sarju G Mehta; Steven Mumm; Daniel Darvish; Alan Pestronk; Michael P Whyte; Virginia E Kimonis
Journal:  Nat Genet       Date:  2004-03-21       Impact factor: 38.330

View more
  68 in total

1.  Global gene profiling of VCP-associated inclusion body myopathy.

Authors:  Angèle Nalbandian; Svetlana Ghimbovschi; Shlomit Radom-Aizik; Eric Dec; Jouni Vesa; Barbara Martin; Susan Knoblach; Charles Smith; Eric Hoffman; Virginia E Kimonis
Journal:  Clin Transl Sci       Date:  2012-04-04       Impact factor: 4.689

2.  Altered intersubunit communication is the molecular basis for functional defects of pathogenic p97 mutants.

Authors:  Wai Kwan Tang; Di Xia
Journal:  J Biol Chem       Date:  2013-11-06       Impact factor: 5.157

Review 3.  Valosin containing protein associated fronto-temporal lobar degeneration: clinical presentation, pathologic features and pathogenesis.

Authors:  C C Weihl
Journal:  Curr Alzheimer Res       Date:  2011-05       Impact factor: 3.498

4.  A progressive translational mouse model of human valosin-containing protein disease: the VCP(R155H/+) mouse.

Authors:  Angèle Nalbandian; Katrina J Llewellyn; Mallikarjun Badadani; Hong Z Yin; Christopher Nguyen; Veeral Katheria; Giles Watts; Jogeshwar Mukherjee; Jouni Vesa; Vincent Caiozzo; Tahseen Mozaffar; John H Weiss; Virginia E Kimonis
Journal:  Muscle Nerve       Date:  2012-11-21       Impact factor: 3.217

5.  A novel mutation in VCP causes Charcot-Marie-Tooth Type 2 disease.

Authors:  Michael A Gonzalez; Shawna M Feely; Fiorella Speziani; Alleene V Strickland; Matt Danzi; Chelsea Bacon; Youjin Lee; Tsui-Fen Chou; Susan H Blanton; Conrad C Weihl; Stephan Zuchner; Michael E Shy
Journal:  Brain       Date:  2014-08-14       Impact factor: 13.501

6.  VCP is essential for mitochondrial quality control by PINK1/Parkin and this function is impaired by VCP mutations.

Authors:  Nam Chul Kim; Emilie Tresse; Regina-Maria Kolaitis; Amandine Molliex; Ruth E Thomas; Nael H Alami; Bo Wang; Aashish Joshi; Rebecca B Smith; Gillian P Ritson; Brett J Winborn; Jennifer Moore; Joo-Yong Lee; Tso-Pang Yao; Leo Pallanck; Mondira Kundu; J Paul Taylor
Journal:  Neuron       Date:  2013-03-14       Impact factor: 17.173

7.  Muscle MRI in muscular dystrophies.

Authors:  Jordi Díaz-Manera; Jaume Llauger; Eduard Gallardo; Isabel Illa
Journal:  Acta Myol       Date:  2015-12

8.  Phenotypic variability in three families with valosin-containing protein mutation.

Authors:  S Spina; A D Van Laar; J R Murrell; R L Hamilton; J K Kofler; F Epperson; M R Farlow; O L Lopez; J Quinlan; S T DeKosky; B Ghetti
Journal:  Eur J Neurol       Date:  2012-08-20       Impact factor: 6.089

9.  Genotype-phenotype studies of VCP-associated inclusion body myopathy with Paget disease of bone and/or frontotemporal dementia.

Authors:  S G Mehta; M Khare; R Ramani; G D J Watts; M Simon; K E Osann; S Donkervoort; E Dec; A Nalbandian; J Platt; M Pasquali; A Wang; T Mozaffar; C D Smith; V E Kimonis
Journal:  Clin Genet       Date:  2012-10-04       Impact factor: 4.438

Review 10.  Paget's disease of bone-genetic and environmental factors.

Authors:  Frederick R Singer
Journal:  Nat Rev Endocrinol       Date:  2015-08-18       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.